Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 51, Issue 4, 2007, Pages 304-313

  Albrecht, H ^a   Denardo, G L ^a   Denardo, S J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast neoplasms; Drug labelling; Prosmtic neoplasms

Indexed keywords

IBRITUMOMAB TIUXETAN; MACROGOL; MONOCLONAL ANTIBODY; MUCIN 1; MUCIN 1 SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TOSITUMOMAB I 131; UNCLASSIFIED DRUG;

BREAST CANCER; CONFERENCE PAPER; CONJUGATION; COVALENT BOND; DRUG APPROVAL; GENE EXPRESSION; GENE INSERTION; GENE STRUCTURE; HUMAN; IMMUNOREACTIVITY; ISOTOPE LABELING; NONHODGKIN LYMPHOMA; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIOIMMUNOTHERAPY;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CA-15-3 ANTIGEN; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MALE; NEOPLASMS, GLANDULAR AND EPITHELIAL; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS;

EID: 37249071981     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (60)

1. Pressman D, Korngold L. The in vivo localization of anti-Wagnerosteogenic sarcoma antibodies. Cancer 1953;6:619-23.
2. Kohler G, Milstein C. Continuous culture of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7.
3. Mach JP, Chatal JF, Lumbroso JD, Buchegger F, Forni M, Ritschard J et al. Tumor localization in patients by radiolabeled monoclonal antibodies against colon carcinoma. Cancer Res 1983;43:5593-600.
4. Buchegger F, Halpern SE, Sutherland RM, Schreyer M, Mach JP. In vitro and in vivo tumor models for studies of distribution of radiolabeled monoclonal antibodies and fragments. Nuklearmedizin 1986;25:207-9.
5. DeNardo SJ, DeNardo GL. Targeted radionuclide therapy for solid tumors: an overview. Int J Radiat Oncol Biol Phys 2006;66:S89-S95.
6. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990;348:552-4.
7. Weiner LM. Fully human therapeutic monoclonal antibodies. J Immunother 2006;29:1-9.
8. Buchegger F, Pelegrin A, Delaloye B, Bischof-Delaloye A, Mach JP. Iodine-131-labeled MAb F(ab′)2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice. J Nucl Med 1990;31:1035-44.
9. Kukis DL, Novak-Hofer I, DeNardo SJ. Cleavable linkers to enhance selectivity of antibody-targeted therapy of cancer. Cancer Biother Radiopharm 2001;16:457-67.
10. DeNardo SJ, Kukis DL, Kroger LA, O'Donnell RT, Lamborn KR, Miers LA et al. Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci U S A 1997;94:4000-4.
11. Gruaz-Guyon A, Raguin O, Barbet J. Recent advances in pretargeted radioimmunotherapy. Curr Med Chem 2005;12:319-38.
12. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006;24:823-34.
13. Urbano N, Papi S, Ginanneschi M, De Santis R, Pace S, Lindstedt R et al. Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT((R))). Eur J Nucl Med Mol Imaging 2007;34:68-77.
14. Carter, P. Bispecific human IgG by design. J Immunol Methods 2001;248:7-15.
15. Tomlinson I, Holliger P. Methods for generating multivalent and bispecific antibody fragments. Methods Enzymol 2000;326:461-79.
16. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990;265:15286-93.
17. Ligtenberg MJ, Kruijshaar L, Buijs F, van Meijer M, Litvinov SV, Hilkens J. Cell-associated episialin is a complex containing two proteins derived from a common precursor. J Biol Chem 1992;267: 6171-7.
18. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 1988;263:12820-3.
19. Taylor-Papadimitriou J, Burchell J, Miles DW, Dalziel M. MUC1 and cancer. Biochim Biophys Acta 1999;1455:301-13.
20. Brayman M, Thathiah A, Carson D. MUC1: a multifunctional cell surface component of reproductive tissue epithelia. Reprod Biol Endocrinol 2004;2:4-12.
21. Zotter S, Hageman C, Lossnitzer A, Mooi WJ, Hilgers J. Tissue and tumor distribution of human polymorphic epthelial mucin. Cancer Rev 1988;11-12:55-101.
22. Barratt-Boyes SM. Making the most of mucin: a novel target for tumor immunotherapy. Cancer Immunol Immunother 1996;43:142-51.
23. Burchell J, Gendler S, Taylor-Papadimitriou J, Girling A, Lewis A, Millis R et al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 1987;47:5476-82.
24. Ceriani RL, Peterson JA, Blank EW, Derek TA. Epitope expression on the breast epithelial mucin. Breast Cancer Res Treat 1992;24:103-13.
25. ten Berge RL, Snijdewint FGM, von Mensdorff-Pouilly S, Poort-Keesom RJJ, Oudejans JJ, Meijer JWR et al. L. MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form. J Clin Pathol 2001;54:933-9.
26. Cao Y, Blohm D, Ghadimi M, Stosiek P, Xing PX, Karsten U. Mucins (MUC1 and MUC3) of gastrointestinal and breast epithelial reveal different and heterogeneous tumor-associated aberrations in glycosylation. J Histochem Cytochem 1997;45:1547-57.
27. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 2005;101: 811-6.
28. Best CJM, Gillespie JW, Yi Y, Chandramouli GVR, Perlmutter MA, Gathright Y et al. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res 2005;11:6823-34.
29. O'Connor JC, Julian J, Lim SD, Carson DD. MUC1 expression in human prostate cancer cell lines and primary tumors. Prostate Cancer Prostatic Dis 2005;8:36-44.
30. Arai T, Fujita K, Fujime M, Irimura T. Expression of sialylated MUC1 in prostate cancer: Relationship to clinical stage and prognosis. Int J Urol 2005;12:654-61.
31. Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 2001;4:295-302.
32. Burke PA, Gregg JP, Bakhtiar B, Beckett LA, DeNardo GL, Albrecht H et al. Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules. Int J Oncol 2006;29:49-55.
33. Price MR, Rye PD, Petrakou E, Murray A, Brady K, Imaj S et al. Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. Tumor Biol 1998;19:1-20.
34. Fontenot JD, Tjandra N, Bu D, Ho C, Montelaro RC, Finn OJ. Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (MACE-1) protein core. Cancer Res 1993;53:5386-94.
35. Peterson JA, Zava DT, Duwe AK, Blank EW, Battifora H, Ceriani RL. Characterization of antigens preferentially expressed on the surface and cytoplasm of breast carcinoma cells identified by monoclonal antibodies against the human milk fat globule. Hybridoma 1990;9:221-35.
36. Kramer EL, DeNardo SJ, Liebes L, Kroger LA, Noz ME, Mizrachi H et al. Radioimmunolocalization of breast carcinoma using BrE-3 monoclonal antibody: phase I study. J Nucl Med 1993;34: 1067-74.
37. Hoogenboom HR. Designing and optimizing library selection strategies for generating high-affinity antibodies. Trends Biotechnol 1997;15:62-70.
38. Winthrop MD, DeNardo SJ, DeNardo GL. Development of a hyperimmune anti-MACE-1 single chain antibody phage display library for targeting breast cancer. Clin Cancer Res 1999;10:3088-94.
39. Winthrop MD, DeNardo SJ, Albrecht H, Mirick GR, Kroger LA, Lamborn KR et al. Selection and characterization of anti-MACE-1 scFvs intended for targeted therapy. Clin Cancer Res 2003;9:3845s-3853s.
40. Adams GP, Schier R, McCall AM, Crawford SM, Wolff EJ, Weiner M et al. Prolonged in vivo tumor retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 1998; 77:1405-12.
41. Chinol M, Casalini P, Maggiolo M, Canevari S, Omodeo ES, Caliceti P et al. Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. Br J Cancer 1998;78:189-97.
42. Padlan EA. Anatomy of the antibody molecule. Mol Immunol 1994;31:169-217.
43. Adams GP, McCartney JE, Tai MS, Oppermann H, Huston JS, Stafford WF et al. Highly specific in vivo tumour targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 1993;53:4026-34.
44. Kipriyanov SM, Dubel S, Breitling F, Konterman RD, Little M. Recombinant single-chain Fv fragments carrying C-terminal cysteine residues: production of bivalent and biotinylated miniantibodies. Mol Immunol 1994;31:1047-58.
45. 2. Bioconjug Chem 1997;8:64-70.
46. Albrecht H, Burke PA, Natarajan A, Xiong CY, Kalicinsky M, DeNardo GL et al. J. Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand. Bioconjug Chem 2004;15:16-26.
47. Natarajan A, Xiong CY, Albrecht H, DeNardo GL, DeNardo SJ. Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals. Bioconjug Chem 2005;16:113-21.
48. Yang K, Basu A, Wang M, Chintala R, Hsieh MC, Li S et al. Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. Protein Eng 2003;16:761-70.
49. Holliger P, Prospero T, Winter G. 'Diabodies': small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A 1993;90: 6444-8.
50. Cochlovius B, Kipriyanov SM, Stassar MJJS, Schumacher J, Benner A, Moldenhauer G et al. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by t cells, tetravalent CD3xCD19 tandem diabody, and CD28 costimulation. Cancer Res 2000;60: 4336-41.
51. Olafsen T, Cheung CW, Yazaki PJ, Li L, Sundaresan G, Gambhir SS et al. Covalent disulfide-linked anti-CEA diabody allow site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng Des Sel 2004;17:21-7.
52. Mack M, Riethmuller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci U S A 1995;92: 7021-5.
53. Goel A, Colcher D, Baranowska-Kortylewicz J, Augustine S, Booth BJM, Pavlinkova G et al. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application. Cancer Res 2000;60:6964-71.
54. Albrecht H, DeNardo GL, DeNardo SJ. Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility. J Immunol Methods 2006;310:100-16.
55. Xiong CY, Natarajan A, Shi XB, DeNardo GL, DeNardo SJ. Development of tumor targeting anti-MACE-1 multimer: effects of di-scFv unpaired cysteine location on PEGylation and tumor binding. Protein Eng Des Sel 2006;19:359-367.
56. Burchell JM, Mungul A, Taylor-Papadimitriou J. O-linked glycosylation in the mammary gland: changes that occur during malignancy. J Mammary Gland Biol Neoplasia 2001;6:355-64.
57. Kubetzko S, Sarkar CA, Pluckthun A. Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol Pharmacol 2005;68:1439-54.
58. Natarajan A, Du W, Xiong CY, DeNardo GL, DeNardo SJ, Gervay-Hague J. Construction of di-scFv through a trivalent alkyne-azide 1,3 dipolar cycloaddition. R Soc Chem Chem Comm. In press 2007.
59. Adams GP, Tai MS, McCartney JE, Marks JD, Stafford WF III, Houston LL et al. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res 2006;12:1599-605.
60. Rossi EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM, Chang CH. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. PNAS 2006;103:6841-6.